β-Blocker dosing in community-based treatment of heart failure
Michael B. Fowler1, Sandra R. Lottes2, Jeanenne J. Nelson3, Mary Ann Lukas2, Edward M. Gilbert4, Barry Greenberg5, Barry M. Massie6, William T. Abraham7, Joseph A. Franciosa1,8
1Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, CA
2GlaxoSmithKline Pharmaceuticals, Philadelphia, PA
3GlaxoSmithKline, Worldwide Epidemiology, Research Triangle Park, NC
4University of Utah Medical Center, Salt Lake City, UT
5University of California San Diego, San Diego, CA
6Veterans Administration Medical Center and University of California San Francisco, San Francisco, CA
7Ohio State University School of Medicine, Columbus, OH
8Mount Sinai School of Medicine and Weill Medical College, Cornell University, New York, NY
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
American Heart Journal
Tập 153
1029-1036
Thông tin tác giả